BioScience Managers Limited

Rex Bionics Plc is engaged in the research and development, manufacture, and commercialization of robotic devices designed to provide physiotherapy to and improve the physical and psychological well-being of people with mobility impairment as a result of spinal cord injury or other neurological trauma, such as stroke or traumatic brain injury, or neurodegenerative disease. The Company develops and commercializes ReX, the hands-free, self-supporting, independently controlled robotic walking device for use in the rehabilitation of people with major mobility impairment. The Company offers two principal products: ReX and ReX P (Personal), which are targeted respectively at the professional neuro-rehabilitation clinic and personal homecare markets. The Company utilizes RAPPER II, which is an open label, single arm, non-randomized, non-comparative registry study of Robot-Assisted Physiotherapy Exercises with the REX Robot powered exercise system preventing unsupported patient ambulation.

Avita is a medical company that specializes in regenerative medicine, chronic wounds, and plastic surgery. It provides a novel approach to skin regeneration. Our products provide innovative treatment solutions derived from the regenerative properties of a patient’s own skin.

Saluda Medical is a commercial-stage medical device company that develops treatments for chronic neurological conditions using a novel closed-loop, dose-control neuromodulation platform. Its novel neuromodulation platform is designed to sense and measure neural responses to stimulation and automatically adjust therapy based on real-time neurophysiological feedback.

Our mission is to be a revolutionary force in the growing US$25 billion global animal pharmaceutical market. Only Nexvet can produce therapeutic antibodies that are 100% customised to target new species – like cats and dogs. Monoclonal antibody therapies have represented a new generation of highly effective, safe and targeted medicines in humans. We think it’s time companion animals reaped the benefits of human medical progress in this field. Nexvet’s unique technology, PETisation™, ensures 100% customisation of a therapy to a new species, reducing the chances of immune challenges, and ensuring a more ‘natural’ fit between the therapy and the patient. Many chronic conditions in pets remain poorly treated by current veterinary therapies, such as pain and various inflammatory diseases– which has guided Nexvet’s focus towards these indications. To ensure we succeed in transforming animal medicine, we’ve brought together a team with an extraordinary global track record in animal and human health. We are working with leading contractors, advisors, drug development partners, academic groups, veterinarians and animal interest groups around the world to develop our pipeline to the highest standards. Senior executives and researchers from the world’s largest animal health brands are counted among our Board, management, and advisors, and together we’re building connections worldwide to make our vision a reality.

AmpliPhi Biosciences is a biopharmaceutical company focused on the development of an internally generated pipeline of naturally occurring viruses called bacteriophage (phage) for the treatment of bacterial infection. Phage-based therapy provides a unique and proven approach to treating a wide variety of bacterial infections and in particular, drug-resistant strains of bacteria that are commonly found in the hospital setting. We have built a drug development and manufacturing platform designed to allow rapid development and production of multiple phage-based therapies. Our plan and success relies on our ability to identify and develop selected phage to eradicate targeted bacterial infections across a wide range of bacterial disease. Initially our phage discovery and development platform will focus efforts in acute and chronic lung, sinus and gastrointestinal (GI) infections. AmpliPhi maintains operations in Richmond, Virginia in the United States, in Colworth Science Park, near London in the United Kingdom, and outside Sydney, NSW, Australia.

Alchemia Limited is a listed Australian biopharmaceutical company (ASX:ACL) with an FDA approved drug (Fondaparinux sodium) and a late stage oncology product pipeline derived from the HyACT platform. In addition, Alchemia has a drug discovery platform, VAST®, derived from Alchemia’s chemistry expertise.

Adherium (previously known as Nexus6) is a privately owned developer and manufacturer of solutions that help patients and their healthcare professionals monitor and increase patient adherence to prescribed therapies, leading to improved disease management and reduced healthcare costs.

Sea Dragon Limited is a New Zealand based food processing company that manufactures fish oils. The company is based in Nelson, New Zealand.

Millenium Biologix Corporation operates as a biomedical company primarily in the United States and Europe. It engages in the development and commercialization of implantable medical devices and skeletal tissue regeneration products for various orthopedic uses. The company offers Skelite, a synthetic bone graft, for healing and replacement. Millenium Biologix also develops Primacoll and Peptos for the stimulation of bone tissue growth. In addition, it offers ACTES, a cell culture and tissue engineering system, which provides automated control over the biological process of tissue engineering. The company was founded in 1986 and is headquartered in Kingston, Canada.

Millenium Biologix Corporation operates as a biomedical company primarily in the United States and Europe. It engages in the development and commercialization of implantable medical devices and skeletal tissue regeneration products for various orthopedic uses. The company offers Skelite, a synthetic bone graft, for healing and replacement. Millenium Biologix also develops Primacoll and Peptos for the stimulation of bone tissue growth. In addition, it offers ACTES, a cell culture and tissue engineering system, which provides automated control over the biological process of tissue engineering. The company was founded in 1986 and is headquartered in Kingston, Canada.